Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 315Lymphoma 282Leukemia 227Precursor Cell Lymphoblastic Leukemia-Lymphoma 216Lymphoma, Non-Hodgkin 178Leukemia, Lymphocytic, Chronic, B-Cell 177Multiple Myeloma 174Lymphoma, Large B-Cell, Diffuse 174Lymphoma, Follicular 142Leukemia, Myeloid, Acute 136Lymphoma, Mantle-Cell 126Hodgkin Disease 125Burkitt Lymphoma 117Myelodysplastic Syndromes 110Lymphoma, Large-Cell, Immunoblastic 89Lymphoma, B-Cell, Marginal Zone 85Recurrence 67Neoplasms, Plasma Cell 62Leukemia, Myeloid, Chronic-Phase 59Neuroblastoma 56Dendritic Cell Sarcoma, Interdigitating 56Leukemia, Myeloid, Accelerated Phase 55Myeloproliferative Disorders 54Melanoma 54Congenital Abnormalities 48Neoplasms 47Leukemia, Myelomonocytic, Chronic 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 45Blast Crisis 45Lymphoma, Large-Cell, Anaplastic 44

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × Cyclophosphamide × Clear all
NCT02737475 2022-01-25

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
166 enrolled 57 charts

Advanced Cancer

NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
398 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡